It is an accepted notion that for HER2-posiitve breast cancer ER-positive disease and ER-negative disease are two distinct entities, as reflected in the differences in pCR rates in neoadjuvant setting [3, 17–21] and differences seen in patterns and incidence of relapse within adjuvant studies [23]. The gene discussed is ERBB2; the disease is glycogen storage disease VI.